Loading market dashboard
ProPhase Labs, Inc.
PRPHHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) shares passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.24 and traded as low as $0.1035. ProPhase Labs shares last traded at $0.1198, with a volume of 56,021 shares trading hands. Wall Street Analyst Weigh In
ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $1.42 and traded as low as $0.1402. ProPhase Labs shares last traded at $0.1503, with a volume of 146,678 shares changing hands. Wall Street Analyst Weigh
$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potential UNIONDALE, NY, April 15, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today reported its financial results for the year ended December 31, 2025 and provided a business update highlighting continued advancement and expansion of its Crown Medical Collections initiative. “We are very encouraged by the scale and progression of activity across our receivables platform,” said Ted Karkus, Chief Executive Officer of ProPhase Labs.
Shares of ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.86 and traded as low as $0.0720. ProPhase Labs shares last traded at $0.0751, with a volume of 37,941 shares traded. Analysts Set New Price Targets
Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided a business update regarding its Crown Medical Collections initiative and related strategic activities.
